Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

Journal of the National Cancer Institute

Volumn 85, Issue 8, 1993, Pages 622-632

  Rosenberg, Steven A ^a   Lotze, Michael T ^a   Yang, James C ^a   Topalian, Suzanne L ^a   Chang, Alfred E ^a   Schwartzentruber, Douglas J ^a   Aebersold, Paul ^a   Leitman, Susan ^b   Linehan, W Marston ^a   Seipp, Claudia A ^a   White, Donald E ^a   Steinberg, Seth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PARACETAMOL; PETHIDINE; RANITIDINE; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILD; CHILL; COLORECTAL CANCER; DIARRHEA; DISORIENTATION; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHODGKIN LYMPHOMA; OLIGURIA; PRIORITY JOURNAL; PRURITUS; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMAN; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKAPHERESIS; MALE; MIDDLE AGE; NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0027529476     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.8.622     Document Type: Article

References (45)

1. Rosenbero SA: Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. JNCI 75:595-603, 1985
2. Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In Important Advances in Oncology (DeVita VT Jr, Heilman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1986, pp 55-91
3. Mulé JJ, Shu S, Schwarz SL, et al: Adoptive immunotherapy of established pulmonary métastasés with LAK cells and recombinant interleukin-2. Science 225:1487-1489, 1984
4. Mulé JJ, Shu S, Rosenberg SA: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 m vivo. J Immunol 135:646-652, 1985
5. Rosenberg SA, Mulé JJ, Spiess PJ, et al: Regression of established pulmonary métastasés and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169-1188, 1985
6. Lafreniere R, Rosenberg SA: Successful therapy of hepatic métastasés from several murine tumors using lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2). Surg Forum 36:392-394, 1985
7. Lafreniere R, Rosenberg SA: Adoptive immunotherapy of murine hepatic métastasés with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273-4280, 1985
8. Papa MZ, Mulé JJ, Rosenberg SA: The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Successful immunotherapy of established pulmonary métastasés from weakly immunogenic and non-immunogenic murine tumors of three distinct histological types. Cancer Res 46:4973-4978, 1986
9. Mazumder A, Eberlein TJ, Grimm EA, et al: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53:896-905, 1984
10. Rosenberg SA: Immunotherapy of cancer by the systemic administration of lymphoid cells plus interieukin-2. J Biol Response Mod 3:501-511, 1984
11. Lotze MT, Frana LW, Sharrow SO, et al: In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134:157-166, 1985
12. Lotze MT, Matory YL, Ettinohausen SE, et al: In vivo administration of purified human interieukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865-2875, 1985
13. Rosenbero SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interieukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
14. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
15. Lotze MT, Chang AE, Seipp CA, et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer Responses, treatment-related morbidity and histologic findings. JAMA 256:3117-3124, 1986
16. DeVita VT Jr, Hellman S, Rosenberg SA: Biologic Therapy of Cancer. Philadelphia: Lippincott, 1991
17. Muul LM, Director EP, Hyatt CL, et al: Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immonol Methods 88:265-275, 1986
18. Muul LM, Nason-Burchenal K, Carter CS, et al: Development of an automated closed system for generation of human lymphokine activated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 101:171-181, 1987
19. Muul LM, Nason-Burchenal K, Hyatt C, et al: Studies of serumfree culture medium in the generation of lymphokine activated killer cells. J Immunol Methods 105:183-192, 1987
20. Aebersold P, Carter CS, Hyatt C, et al: A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials. J Immunol Methods 112:1-7, 1988
21. Kaplan EL, Meier P: Non-parametric estimation from incomplete observanons. J Am Stat Assoc 53:457-481, 1958.
22. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
23. Belldegrun A, Webb DE, Austin HA, et al: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106:817-822, 1987
24. Ettinghausen SE, Moore JG, White DE, et al: Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69:1654-1660, 1987
25. Denicoff KD, Rubinow DR, Papa MZ, et al: The neuropsychiatrie effects of the treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293-300, 1987
26. Gaspari AA, Lotze MT, Rosenberg SA, et al: Dermatologic changes associated with interleukin 2 administration. JAMA 258:1624-1629, 1987
27. Saris SC, Rosenberg SA, Friedman RB, et al: Penetration of recombinant interleukin 2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69:29-34, 1988
28. Oonibene FP, Rosenberg SA, Lotze M, et al: Interieukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750-754, 1988
29. Webb DE, Austin HA, Belldegrun A, et al: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 30:141-145, 1988
30. Schwartzentruber D, Lotze MT, Rosenbero SA: Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer 62:2350-2353, 1988
31. Lee RE, Gaspari AA, Lotze MT, et al: Interieukin-2 and psoriasis. Arch Dermatol 124:1811-1815, 1988.
32. Lee RE, Lotze MT, Skibber JM, et al: Cardiorespiratory effects of immunotherapy with interieukin-2. J Clin Oncol 7:7-20, 1989
33. Belldegrun A, Webb DE, Austin HA 3rd, et al: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer Effect of pre-therapy nephrectomy. J Urol 141:499-503, 1989
34. Denicoff KD, Durkin TM, Lotze MT, et al: The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69:402-410, 1989
35. Kragel AH, Travis WD, Steis RG, et al: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66:1513-1516, 1990
36. Bock SN, 1 -ff RE, Fisher B, et al: A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8:161-169, 1990
37. Atkins MB, Mier JW, Parkinson DR, et al: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563, 1988
38. Schwartzentruber DJ, White DE, Zweig MH, et al: Thyroid dysfunction associated with immunotherapy of cancer patients. Cancer 68:2384-2390, 1991
39. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735-1742, 1986
40. West WH, Tauer KW, Yannelli JR: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987
41. Weiss GR, Margoun KA, Aronson FR, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10:275-281, 1992
42. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
43. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 79:1067-1075, 1987
44. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 319:1676-1680, 1988
45. Rosenberg SA, Aebersold PM, Cornetta K, et al: Gene transfer into humans—immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570-578, 1990